PeptiDream Inc (PPTDF)
17.00
0.00 (0.00%)
USD |
OTCM |
Nov 14, 16:00
PeptiDream Revenue (Quarterly): 204.69M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 204.69M |
March 31, 2024 | 28.47M |
December 31, 2023 | 41.78M |
September 30, 2023 | 90.82M |
June 30, 2023 | 32.52M |
March 31, 2023 | 37.58M |
December 31, 2022 | 110.96M |
September 30, 2022 | 44.77M |
June 30, 2022 | 35.54M |
March 31, 2022 | 3.611M |
December 31, 2021 | 14.10M |
September 30, 2021 | 44.54M |
June 30, 2021 | 42.07M |
March 31, 2021 | 13.95M |
December 31, 2020 | 75.11M |
September 30, 2020 | 6.832M |
June 30, 2020 | 25.22M |
March 31, 2020 | 3.616M |
September 30, 2019 | 3.682M |
June 30, 2019 | 39.04M |
March 31, 2019 | 8.236M |
December 31, 2018 | 12.98M |
Date | Value |
---|---|
September 30, 2018 | 4.985M |
June 30, 2018 | 48.50M |
March 31, 2018 | 2.066M |
December 31, 2017 | 6.569M |
September 30, 2017 | 1.545M |
June 30, 2017 | 31.31M |
March 31, 2017 | 2.229M |
December 31, 2016 | 3.369M |
September 30, 2016 | 7.779M |
June 30, 2016 | 15.24M |
March 31, 2016 | 14.29M |
December 31, 2015 | 5.314M |
September 30, 2015 | 3.186M |
June 30, 2015 | 15.98M |
March 31, 2015 | 1.241M |
December 31, 2014 | 2.155M |
September 30, 2014 | 1.360M |
June 30, 2014 | 2.170M |
March 31, 2014 | 1.258M |
December 31, 2013 | 2.922M |
September 30, 2013 | 1.765M |
June 30, 2013 | 1.962M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.611M
Minimum
Mar 2022
204.69M
Maximum
Jun 2024
47.56M
Average
36.56M
Median
Revenue (Quarterly) Benchmarks
Takeda Pharmaceutical Co Ltd | 7.918B |
Nxera Pharma Co Ltd | 62.36M |
Healios KK | 3.195M |
AnGes Inc | 0.8352M |
SanBio Co Ltd | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 120.39M |
Total Expenses (Quarterly) | 39.52M |
EPS Diluted (Quarterly) | 0.9276 |
Enterprise Value | 2.175B |
Gross Profit Margin (Quarterly) | 89.26% |
Profit Margin (Quarterly) | 58.82% |
Earnings Yield | 6.38% |
Operating Earnings Yield | 9.59% |
Normalized Earnings Yield | 6.384 |